SCHEMBL1401770

SCHEMBL1401770

CCOc1cc2c(c(OC)c1OC)-c1ccc(SC)c(=O)cc1[C@@H](N)CC2

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TUBB4A P04350 11/20 0.83
TUBB P07437 11/20 0.83
TUBA3C P0DPH7 11/20 0.83
TUBA1B P68363 11/20 0.83
TUBA4A P68366 11/20 0.83
TUBB4B P68371 11/20 0.83
TUBB3 Q13509 11/20 0.83
TUBB2A Q13885 11/20 0.83
TUBB8 Q3ZCM7 11/20 0.83
TUBA3E Q6PEY2 11/20 0.83
TUBA1A Q71U36 11/20 0.83
TUBA1C Q9BQE3 11/20 0.83
TUBB6 Q9BUF5 11/20 0.83
TUBB2B Q9BVA1 11/20 0.83
TUBB1 Q9H4B7 11/20 0.83
NR0B1 P51843 1/20 0.83
GNG2 P59768 1/20 0.65
GNB1 P62873 1/20 0.65
KDM4E B2RXH2 1/20 0.62
USP2 O75604 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12091269 1.00 TUBB4A (0.83) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL30418517 0.91 TUBB4A (1.00) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL5434553 0.91 TUBB4A (1.00) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL1401455 0.91 TUBB4A (1.00) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL12091262 0.89 TUBB4A (0.78) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL18866851 0.87 GNG2 (0.69) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL12094188 0.87 TUBB4A (0.63) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL1401409 0.86 TUBB4A (0.83) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL2619296 0.86 GNG2 (0.67) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL21104787 0.86 GNG2 (0.84) TUBB4ATUBBTUBA3CTUBA1BTUBA4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210283092-A1 METHODS AND USES OF COLCHICINE DERIVATIVES ALBERTA HEALTH SERVICES (CA) 2021-09-16 US disclosed
US-20210283092-A1 METHODS AND USES OF COLCHICINE DERIVATIVES ALBERTA HEALTH SERVICES (CA) 2021-09-16 US disclosed
EP-3813821-A1 METHODS AND USES OF COLCHICINE DERIVATIVES Alberta Health Services (CA) 2021-05-05 EP disclosed
EP-2470499-B1 NOVEL COLCHICINE DERIVATIVES, METHODS AND USES THEREOF ALBERTA HEALTH SERVICES (CA) 2019-06-12 EP disclosed
EP-2452931-B1 METHOD FOR PREPARING TRICYCLIC DERIVATIVES JE IL PHARMACEUTICAL CO LTD (KR) 2017-05-17 EP disclosed
EP-2452931-B1 METHOD FOR PREPARING TRICYCLIC DERIVATIVES JE IL PHARMACEUTICAL CO LTD (KR) 2017-05-17 EP disclosed
US-8742160-B2 Method for preparing tricyclic derivatives JE IL PHARMACEUTICAL CO., LTD. (KR) 2014-06-03 US disclosed
US-8742160-B2 Method for preparing tricyclic derivatives JE IL PHARMACEUTICAL CO., LTD. (KR) 2014-06-03 US disclosed
EP-2452931-A2 METHOD FOR PREPARING TRICYCLIC DERIVATIVES Jeil Pharmaceutical Co., Ltd. (KR) 2012-05-16 EP disclosed
US-20120101296-A1 METHOD FOR PREPARING TRICYCLIC DERIVATIVES JE IL PHARMACEUTICAL CO., LTD. (KR) 2012-04-26 US disclosed
US-20120101296-A1 METHOD FOR PREPARING TRICYCLIC DERIVATIVES JE IL PHARMACEUTICAL CO., LTD. (KR) 2012-04-26 US disclosed
EP-1646608-B1 TRICYCLIC DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM JE IL PHARMACEUTICAL CO LTD (KR) 2011-03-02 EP disclosed
US-20070179143-A1 Tricyclic derivatives or pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them JE IL PHARMACEUTICAL CO., LTD. (KR) 2007-08-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070179143-A1 Tricyclic derivatives or pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them VEGFA, TUBB3, TUBA3C TUBB4A 10/4885TUBB 7/4885TUBA3C 3/4885
US-20120101296-A1 METHOD FOR PREPARING TRICYCLIC DERIVATIVES NISCH, CA3, CYP51A1 TUBB4A 2554/4885TUBB 3311/4885TUBA3C 2667/4885
US-20210283092-A1 METHODS AND USES OF COLCHICINE DERIVATIVES IL1B, IL6, TUBB TUBB4A 18/4885TUBB 3/4885TUBA3C 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.